BRÈVE

sur VALNEVA (EPA:VLA)

Valneva Achieves UK Approval for World's First Chikungunya Vaccine

Graphique de l'évolution du cours de l'action VALNEVA (EPA:VLA).

Valneva SE announced that the UK Medicines and Healthcare products Regulatory Agency has approved their chikungunya vaccine, IXCHIQ®, for individuals 18 and older. This marks the vaccine's fourth regulatory approval following prior authorizations in the United States, Europe, and Canada. Manufactured in Scotland, the single-dose vaccine showed a strong immune response in clinical trials. Valneva plans to seek further label expansions, targeting younger age groups.

The vaccine's approval coincides with rising chikungunya cases, particularly in India, a popular destination for UK travelers. This approval addresses both traveler safety and public health concerns over potential disease transmission upon return to the UK.

The decision aligns with global efforts to increase vaccine accessibility in endemic regions. Partnerships, including those with CEPI and the Serum Institute of India, aim to provide affordable vaccine options for low and middle-income countries.

R. P.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VALNEVA